Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Xeris Biopharma Holdings, Inc.XERS · Entity 4670 | Director | June 04, 2026 | June 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Xeris Biopharma Holdings, Inc.
Report date June 04, 2026 · Filed June 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 113,359 |
Reported balance
After 2026-06-04 transaction · row 1
1 source rowRow 1 · 2026-06-04 · Grant · Acquired 24,193 · Balance 113,359 F1: These shares were acquired pursuant to a restricted stock unit grant under the Company's 2018 Stock Option and Incentive Plan (the "Plan"). Each restricted stock represents a contingent right to receive one share of the Company's common stock. These shares shall vest in full upon the earlier to occur of June 4, 2026 or the date of the Company's next annual meeting of stockholders, subject to continued service through such vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.15 · Expires 2036-06-04 | Direct | 32,996 |
Reported balance
After 2026-06-04 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-04 · Grant · Acquired 32,996 · Balance 32,996 F2: These stock options were acquired pursuant to a grant under the Plan. These stock options shall vest in full upon the earlier to occur of June 4, 2026 or the date of the Company's next annual meeting of stockholders, subject to continued service through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were acquired pursuant to a restricted stock unit grant under the Company's 2018 Stock Option and Incentive Plan (the "Plan"). Each restricted stock represents a contingent right to receive one share of the Company's common stock. These shares shall vest in full upon the earlier to occur of June 4, 2026 or the date of the Company's next annual meeting of stockholders, subject to continued service through such vesting date.
F2: These stock options were acquired pursuant to a grant under the Plan. These stock options shall vest in full upon the earlier to occur of June 4, 2026 or the date of the Company's next annual meeting of stockholders, subject to continued service through such vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Verona Pharma plc
Report date October 07, 2025 · Filed October 08, 2025
Section 16 reporting ended · disclosed 2025-10-08. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 0 |
Last balance in matching sequence
After 2025-10-07 transaction · row 3
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rowsRow 1 · 2025-10-07 · Disposition to issuer · Disposed 23,176 · Balance 0 F1: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F2: Represents Ordinary Shares of the Issuer acquired from the Reporting Person by means of a scheme of arrangement (the "Scheme of Arrangement") under Part 26 of the UK Companies Act 2006, pursuant to a transaction agreement, dated as of July 8, 2025 (the "Transaction Agreement"), by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company ("Parent") and Vol Holdings LLC, a Delaware limited liability company and wholly owned subsidiary of Parent ("Bidco"). F3: At the effective time of the Scheme of Arrangement (the "Effective Time"), each holder of the Scheme Shares (as defined in the Scheme of Arrangement) became entitled to receive $13.375 in cash per Scheme Share, without interest and net of any applicable withholding taxes. Because each ADS represents a beneficial ownership interest in eight (8) Ordinary Shares of the Issuer, holders of ADSs as of the Effective Time became entitled to receive eight (8) times the foregoing cash amount, or $107 in cash, without interest and net of any applicable withholding taxes, per ADS (the "ADS Consideration"). Row 2 · 2025-10-07 · Exercise / conversion · Acquired 72,000 · Balance 72,000 F1: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F4: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding time-based restricted share unit award ("RSU Award"), unless agreed otherwise, became fully vested, and at the Effective Time, was automatically converted into the right to receive an amount in cash (without interest and subject to all required withholding taxes) equal to the product of (i) the aggregate number of ADSs underlying such RSU Award and (ii) the ADS Consideration. Row 3 · 2025-10-07 · Disposition to issuer · Disposed 72,000 · Balance 0 F1: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F4: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding time-based restricted share unit award ("RSU Award"), unless agreed otherwise, became fully vested, and at the Effective Time, was automatically converted into the right to receive an amount in cash (without interest and subject to all required withholding taxes) equal to the product of (i) the aggregate number of ADSs underlying such RSU Award and (ii) the ADS Consideration. |
| Restricted Share UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2025-10-07 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-10-07 · Exercise / conversion · Disposed 72,000 · Balance 0 F5: Represents an award of RSUs covering ADSs, which is presented in terms of the equivalent number of Ordinary Shares underlying the ADSs. Each RSU represents a contingent right to receive one (1) ADS of the Issuer. Each ADS represents eight (8) Ordinary Shares of the Issuer. The RSUs have no expiration date. F4: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding time-based restricted share unit award ("RSU Award"), unless agreed otherwise, became fully vested, and at the Effective Time, was automatically converted into the right to receive an amount in cash (without interest and subject to all required withholding taxes) equal to the product of (i) the aggregate number of ADSs underlying such RSU Award and (ii) the ADS Consideration. F1: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. |
| Share Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.60 · Expires 2032-03-13 | Direct | 0 |
Reported balance
After 2025-10-07 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-10-07 · Disposition to issuer · Disposed 288,000 · Balance 0 F6: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding share option became fully vested, to the extent unvested, and at the Effective Time, each share option that had an exercise price less than the ADS Consideration was automatically converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of ADSs underlying such share option and (ii) the excess, if any, of (a) an amount equal to the ADS Consideration over (b) the exercise price of such share option. F1: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. |
| Share Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.67 · Expires 2033-04-27 | Direct | 0 |
Reported balance
After 2025-10-07 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2025-10-07 · Disposition to issuer · Disposed 96,000 · Balance 0 F6: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding share option became fully vested, to the extent unvested, and at the Effective Time, each share option that had an exercise price less than the ADS Consideration was automatically converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of ADSs underlying such share option and (ii) the excess, if any, of (a) an amount equal to the ADS Consideration over (b) the exercise price of such share option. F1: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. |
| Share Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.93 · Expires 2034-04-28 | Direct | 0 |
Reported balance
After 2025-10-07 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2025-10-07 · Disposition to issuer · Disposed 240,000 · Balance 0 F6: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding share option became fully vested, to the extent unvested, and at the Effective Time, each share option that had an exercise price less than the ADS Consideration was automatically converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of ADSs underlying such share option and (ii) the excess, if any, of (a) an amount equal to the ADS Consideration over (b) the exercise price of such share option. F1: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.
F2: Represents Ordinary Shares of the Issuer acquired from the Reporting Person by means of a scheme of arrangement (the "Scheme of Arrangement") under Part 26 of the UK Companies Act 2006, pursuant to a transaction agreement, dated as of July 8, 2025 (the "Transaction Agreement"), by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company ("Parent") and Vol Holdings LLC, a Delaware limited liability company and wholly owned subsidiary of Parent ("Bidco").
F3: At the effective time of the Scheme of Arrangement (the "Effective Time"), each holder of the Scheme Shares (as defined in the Scheme of Arrangement) became entitled to receive $13.375 in cash per Scheme Share, without interest and net of any applicable withholding taxes. Because each ADS represents a beneficial ownership interest in eight (8) Ordinary Shares of the Issuer, holders of ADSs as of the Effective Time became entitled to receive eight (8) times the foregoing cash amount, or $107 in cash, without interest and net of any applicable withholding taxes, per ADS (the "ADS Consideration").
F4: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding time-based restricted share unit award ("RSU Award"), unless agreed otherwise, became fully vested, and at the Effective Time, was automatically converted into the right to receive an amount in cash (without interest and subject to all required withholding taxes) equal to the product of (i) the aggregate number of ADSs underlying such RSU Award and (ii) the ADS Consideration.
F5: Represents an award of RSUs covering ADSs, which is presented in terms of the equivalent number of Ordinary Shares underlying the ADSs. Each RSU represents a contingent right to receive one (1) ADS of the Issuer. Each ADS represents eight (8) Ordinary Shares of the Issuer. The RSUs have no expiration date.
F6: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding share option became fully vested, to the extent unvested, and at the Effective Time, each share option that had an exercise price less than the ADS Consideration was automatically converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of ADSs underlying such share option and (ii) the excess, if any, of (a) an amount equal to the ADS Consideration over (b) the exercise price of such share option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 04, 2026 Filed Jun 5, 2026 22:16 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | GrantStock Option (Right to Buy) · Derivative | 32,996 | $6.15 Strike: $6.15 | $202,925.40 |
DisclosureSEC source: 0001916987-26-000004 · wk-form4_1780697773.xml · derivative · entry 2 Brady James Aloysius · CIK 0001916987 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,996 Underlying: Common Stock · 32,996 shares Expires 2036-06-04 F2 · derivative.exercise_date: These stock options were acquired pursuant to a grant under the Plan. These stock options shall vest in full upon the earlier to occur of June 4, 2026 or the date of the Company's next annual meeting of stockholders, subject to continued service through such vesting date. Read SEC document |
| June 04, 2026 Filed Jun 5, 2026 22:16 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | GrantCommon Stock | 24,193 | $0.00 | $0.00 |
DisclosureSEC source: 0001916987-26-000004 · wk-form4_1780697773.xml · nonDerivative · entry 1 Brady James Aloysius · CIK 0001916987 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 113,359 F1 · shares: These shares were acquired pursuant to a restricted stock unit grant under the Company's 2018 Stock Option and Incentive Plan (the "Plan"). Each restricted stock represents a contingent right to receive one share of the Company's common stock. These shares shall vest in full upon the earlier to occur of June 4, 2026 or the date of the Company's next annual meeting of stockholders, subject to continued service through such vesting date. Read SEC document |
| March 30, 2026 Filed Apr 1, 2026 21:54 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | SaleCommon Stock | 10,834 | $5.54 | $60,035.53 |
DisclosureSEC source: 0001916987-26-000002 · wk-form4_1775080462.xml · nonDerivative · entry 1 Brady James Aloysius · CIK 0001916987 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 89,166 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.290 to $5.630, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| October 07, 2025 Filed Oct 8, 2025 20:32 UTC | Verona Pharma plc VRNA · Entity 74409 | Disposition to issuerShare Options (Right to Buy) · Derivative | 240,000 | Not disclosed Strike: $1.93 | Not disclosed |
DisclosureSEC source: 0001104659-25-097946 · tm2528014-3_4seq1.xml · derivative · entry 7 Brady James Aloysius · CIK 0001916987 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 240,000 shares Expires 2034-04-28 F6 · price: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding share option became fully vested, to the extent unvested, and at the Effective Time, each share option that had an exercise price less than the ADS Consideration was automatically converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of ADSs underlying such share option and (ii) the excess, if any, of (a) an amount equal to the ADS Consideration over (b) the exercise price of such share option. F6 · derivative.exercise_date: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding share option became fully vested, to the extent unvested, and at the Effective Time, each share option that had an exercise price less than the ADS Consideration was automatically converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of ADSs underlying such share option and (ii) the excess, if any, of (a) an amount equal to the ADS Consideration over (b) the exercise price of such share option. F1 · derivative.underlying: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. Read SEC document |
| October 07, 2025 Filed Oct 8, 2025 20:32 UTC | Verona Pharma plc VRNA · Entity 74409 | Disposition to issuerShare Options (Right to Buy) · Derivative | 96,000 | Not disclosed Strike: $2.67 | Not disclosed |
DisclosureSEC source: 0001104659-25-097946 · tm2528014-3_4seq1.xml · derivative · entry 6 Brady James Aloysius · CIK 0001916987 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 96,000 shares Expires 2033-04-27 F6 · price: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding share option became fully vested, to the extent unvested, and at the Effective Time, each share option that had an exercise price less than the ADS Consideration was automatically converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of ADSs underlying such share option and (ii) the excess, if any, of (a) an amount equal to the ADS Consideration over (b) the exercise price of such share option. F6 · derivative.exercise_date: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding share option became fully vested, to the extent unvested, and at the Effective Time, each share option that had an exercise price less than the ADS Consideration was automatically converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of ADSs underlying such share option and (ii) the excess, if any, of (a) an amount equal to the ADS Consideration over (b) the exercise price of such share option. F1 · derivative.underlying: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. Read SEC document |
| October 07, 2025 Filed Oct 8, 2025 20:32 UTC | Verona Pharma plc VRNA · Entity 74409 | Disposition to issuerShare Options (Right to Buy) · Derivative | 288,000 | Not disclosed Strike: $0.60 | Not disclosed |
DisclosureSEC source: 0001104659-25-097946 · tm2528014-3_4seq1.xml · derivative · entry 5 Brady James Aloysius · CIK 0001916987 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 288,000 shares Expires 2032-03-13 F6 · price: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding share option became fully vested, to the extent unvested, and at the Effective Time, each share option that had an exercise price less than the ADS Consideration was automatically converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of ADSs underlying such share option and (ii) the excess, if any, of (a) an amount equal to the ADS Consideration over (b) the exercise price of such share option. F6 · derivative.exercise_date: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding share option became fully vested, to the extent unvested, and at the Effective Time, each share option that had an exercise price less than the ADS Consideration was automatically converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of ADSs underlying such share option and (ii) the excess, if any, of (a) an amount equal to the ADS Consideration over (b) the exercise price of such share option. F1 · derivative.underlying: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. Read SEC document |
| October 07, 2025 Filed Oct 8, 2025 20:32 UTC | Verona Pharma plc VRNA · Entity 74409 | Exercise / conversionRestricted Share Unit · Derivative | 72,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-25-097946 · tm2528014-3_4seq1.xml · derivative · entry 4 Brady James Aloysius · CIK 0001916987 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 72,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · security: Represents an award of RSUs covering ADSs, which is presented in terms of the equivalent number of Ordinary Shares underlying the ADSs. Each RSU represents a contingent right to receive one (1) ADS of the Issuer. Each ADS represents eight (8) Ordinary Shares of the Issuer. The RSUs have no expiration date. F4 · derivative.exercise_price: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding time-based restricted share unit award ("RSU Award"), unless agreed otherwise, became fully vested, and at the Effective Time, was automatically converted into the right to receive an amount in cash (without interest and subject to all required withholding taxes) equal to the product of (i) the aggregate number of ADSs underlying such RSU Award and (ii) the ADS Consideration. F4 · price: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding time-based restricted share unit award ("RSU Award"), unless agreed otherwise, became fully vested, and at the Effective Time, was automatically converted into the right to receive an amount in cash (without interest and subject to all required withholding taxes) equal to the product of (i) the aggregate number of ADSs underlying such RSU Award and (ii) the ADS Consideration. F4 · derivative.exercise_date: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding time-based restricted share unit award ("RSU Award"), unless agreed otherwise, became fully vested, and at the Effective Time, was automatically converted into the right to receive an amount in cash (without interest and subject to all required withholding taxes) equal to the product of (i) the aggregate number of ADSs underlying such RSU Award and (ii) the ADS Consideration. F4 · derivative.expiration_date: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding time-based restricted share unit award ("RSU Award"), unless agreed otherwise, became fully vested, and at the Effective Time, was automatically converted into the right to receive an amount in cash (without interest and subject to all required withholding taxes) equal to the product of (i) the aggregate number of ADSs underlying such RSU Award and (ii) the ADS Consideration. F1 · derivative.underlying: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. Read SEC document |
| October 07, 2025 Filed Oct 8, 2025 20:32 UTC | Verona Pharma plc VRNA · Entity 74409 | Disposition to issuerOrdinary Shares | 72,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-25-097946 · tm2528014-3_4seq1.xml · nonDerivative · entry 3 Brady James Aloysius · CIK 0001916987 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · security: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F4 · price: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding time-based restricted share unit award ("RSU Award"), unless agreed otherwise, became fully vested, and at the Effective Time, was automatically converted into the right to receive an amount in cash (without interest and subject to all required withholding taxes) equal to the product of (i) the aggregate number of ADSs underlying such RSU Award and (ii) the ADS Consideration. Read SEC document |
| October 07, 2025 Filed Oct 8, 2025 20:32 UTC | Verona Pharma plc VRNA · Entity 74409 | Exercise / conversionOrdinary Shares | 72,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-25-097946 · tm2528014-3_4seq1.xml · nonDerivative · entry 2 Brady James Aloysius · CIK 0001916987 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F4 · price: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding time-based restricted share unit award ("RSU Award"), unless agreed otherwise, became fully vested, and at the Effective Time, was automatically converted into the right to receive an amount in cash (without interest and subject to all required withholding taxes) equal to the product of (i) the aggregate number of ADSs underlying such RSU Award and (ii) the ADS Consideration. Read SEC document |
| October 07, 2025 Filed Oct 8, 2025 20:32 UTC | Verona Pharma plc VRNA · Entity 74409 | Disposition to issuerOrdinary Shares | 23,176 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-25-097946 · tm2528014-3_4seq1.xml · nonDerivative · entry 1 Brady James Aloysius · CIK 0001916987 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · security: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F2 · price: Represents Ordinary Shares of the Issuer acquired from the Reporting Person by means of a scheme of arrangement (the "Scheme of Arrangement") under Part 26 of the UK Companies Act 2006, pursuant to a transaction agreement, dated as of July 8, 2025 (the "Transaction Agreement"), by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company ("Parent") and Vol Holdings LLC, a Delaware limited liability company and wholly owned subsidiary of Parent ("Bidco"). F3 · price: At the effective time of the Scheme of Arrangement (the "Effective Time"), each holder of the Scheme Shares (as defined in the Scheme of Arrangement) became entitled to receive $13.375 in cash per Scheme Share, without interest and net of any applicable withholding taxes. Because each ADS represents a beneficial ownership interest in eight (8) Ordinary Shares of the Issuer, holders of ADSs as of the Effective Time became entitled to receive eight (8) times the foregoing cash amount, or $107 in cash, without interest and net of any applicable withholding taxes, per ADS (the "ADS Consideration"). Read SEC document |
| August 01, 2025 Filed Aug 6, 2025 00:24 UTC | Verona Pharma plc VRNA · Entity 74409 | Exercise / conversionRestricted Stock Units · Derivative | 24,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-074391 · tm2522566-7_4seq1.xml · derivative · entry 3 Brady James Aloysius · CIK 0001916987 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,000 Underlying: Ordinary Shares · 24,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · security: Represents an award of RSUs covering ADSs, which is presented in terms of the equivalent number of Ordinary Shares underlying the ADSs. Each RSU represents a contingent right to receive one (1) ADS of the Issuer. Each ADS represents eight (8) Ordinary Shares of the Issuer. The RSUs have no expiration date. F5 · derivative.exercise_price: Represents an award of RSUs covering ADSs, which is presented in terms of the equivalent number of Ordinary Shares underlying the ADSs. Each RSU represents a contingent right to receive one (1) ADS of the Issuer. Each ADS represents eight (8) Ordinary Shares of the Issuer. The RSUs have no expiration date. F6 · derivative.exercise_date: The RSUs vest as to 25% of the total shares on each of August 1, 2025, November 1, 2025, February 1, 2026 and May 1, 2026 subject to the Reporting Person's continued service to the Issuer on each vesting date. F5 · derivative.expiration_date: Represents an award of RSUs covering ADSs, which is presented in terms of the equivalent number of Ordinary Shares underlying the ADSs. Each RSU represents a contingent right to receive one (1) ADS of the Issuer. Each ADS represents eight (8) Ordinary Shares of the Issuer. The RSUs have no expiration date. F1 · derivative.underlying: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. Read SEC document |
| August 01, 2025 Filed Aug 6, 2025 00:24 UTC | Verona Pharma plc VRNA · Entity 74409 | SaleOrdinary Shares | 824 | $13.14 | $10,830.41 |
DisclosureSEC source: 0001104659-25-074391 · tm2522566-7_4seq1.xml · nonDerivative · entry 2 Brady James Aloysius · CIK 0001916987 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,176 F1 · security: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F2 · kind: The sale reported in the Form 4 represents a mandatory "sell-to-cover" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of the restricted stock units ("RSUs"). F3 · price: The price reported represents the sale price of the ADSs divided by eight (8). F4 · balance_after: Consists of 23,176 Ordinary Shares represented by 2,897 ADSs. Read SEC document |
| August 01, 2025 Filed Aug 6, 2025 00:24 UTC | Verona Pharma plc VRNA · Entity 74409 | Exercise / conversionOrdinary Shares | 24,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-074391 · tm2522566-7_4seq1.xml · nonDerivative · entry 1 Brady James Aloysius · CIK 0001916987 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. Read SEC document |
| April 25, 2025 Filed Apr 29, 2025 21:09 UTC | Verona Pharma plc VRNA · Entity 74409 | GrantRestricted Share Units · Derivative | 96,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-041387 · tm2513544-2_4seq1.xml · derivative · entry 1 Brady James Aloysius · CIK 0001916987 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,000 Underlying: Ordinary Shares · 96,000 shares Expires not disclosed F1 · security: Represents an award of Restricted Share Units ("RSUs") covering American Depositary Shares ("ADSs"). Each RSU represents a contingent right to receive one (1) ADS of the Issuer. Each ADS represents eight (8) Ordinary Shares of the Issuer. The RSUs have no expiration date. F1 · derivative.exercise_price: Represents an award of Restricted Share Units ("RSUs") covering American Depositary Shares ("ADSs"). Each RSU represents a contingent right to receive one (1) ADS of the Issuer. Each ADS represents eight (8) Ordinary Shares of the Issuer. The RSUs have no expiration date. F1 · shares: Represents an award of Restricted Share Units ("RSUs") covering American Depositary Shares ("ADSs"). Each RSU represents a contingent right to receive one (1) ADS of the Issuer. Each ADS represents eight (8) Ordinary Shares of the Issuer. The RSUs have no expiration date. F2 · derivative.exercise_date: The RSUs vest as to 25% of the total shares on each of August 1, 2025, November 1, 2025, February 1, 2026 and May 1, 2026 subject to the Reporting Person's continued service to the Issuer on each vesting date. F1 · derivative.expiration_date: Represents an award of Restricted Share Units ("RSUs") covering American Depositary Shares ("ADSs"). Each RSU represents a contingent right to receive one (1) ADS of the Issuer. Each ADS represents eight (8) Ordinary Shares of the Issuer. The RSUs have no expiration date. Read SEC document |
| March 28, 2025 Filed Mar 28, 2025 20:45 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | GrantCommon Stock | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001867096-25-000058 · wk-form4_1743194694.xml · nonDerivative · entry 1 Brady James Aloysius · CIK 0001916987 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 F1 · shares: These shares were acquired pursuant to a restricted stock unit award under the Company's 2018 Stock Option and Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. These shares shall vest in equal annual installments over three years, subject to continued service on the Company's Board of Directors through such vesting date. Read SEC document |
| April 29, 2024 Filed Apr 30, 2024 20:15 UTC | Verona Pharma plc VRNA · Entity 74409 | GrantShare Options (Right to Buy) · Derivative | 240,000 | $0.00 Strike: $1.93 | $0.00 |
DisclosureSEC source: 0001104659-24-054942 · tm2412993-1_4seq1.xml · derivative · entry 1 Brady James Aloysius · CIK 0001916987 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 240,000 Underlying: Ordinary Shares · 240,000 shares Expires 2034-04-28 F1 · derivative.exercise_price: The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares, each of which represents eight (8) Ordinary Shares of the Issuer. F1 · shares: The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares, each of which represents eight (8) Ordinary Shares of the Issuer. F2 · derivative.exercise_date: The option vests and becomes exercisable as to 25% on each of July 29, 2024, October 29, 2024, January 29, 2025 and April 29, 2025. F1 · derivative.underlying_shares: The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares, each of which represents eight (8) Ordinary Shares of the Issuer. F1 · balance_after: The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares, each of which represents eight (8) Ordinary Shares of the Issuer. Read SEC document |
| April 28, 2023 Filed Apr 28, 2023 20:16 UTC | Verona Pharma plc VRNA · Entity 74409 | GrantShare Options (Right to Buy) · Derivative | 96,000 | $0.00 Strike: $2.67 | $0.00 |
DisclosureSEC source: 0001104659-23-052990 · tm2314094-1_4seq1.xml · derivative · entry 1 Brady James Aloysius · CIK 0001916987 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,000 Underlying: Ordinary Shares · 96,000 shares Expires 2033-04-27 F1 · derivative.exercise_price: The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F1 · shares: The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F2 · derivative.exercise_date: The option vests and becomes exercisable as to 25% on each of July 28, 2023, October 28, 2023, January 28, 2024 and April 28, 2024. F1 · derivative.underlying_shares: The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F1 · balance_after: The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. Read SEC document |
| March 14, 2022 Filed Mar 16, 2022 10:04 UTC | Verona Pharma plc VRNA · Entity 74409 | GrantShare Options (Right to Buy) · Derivative | 288,000 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0001104659-22-034156 · tm229323-2_4seq1.xml · derivative · entry 1 Brady James Aloysius · CIK 0001916987 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 288,000 Underlying: Ordinary Shares · 288,000 shares Expires 2032-03-13 F1 · derivative.exercise_price: The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F1 · shares: The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F2 · derivative.exercise_date: The option vests and becomes exercisable as to 25% on August 1, 2022, 25% on November 1, 2022, 25% on February 1, 2023 and 25% on May 1, 2023. F1 · derivative.underlying_shares: The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F1 · balance_after: The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.